Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.52 |
| ▸ | PAK4 | O96013 | 11/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.50 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.50 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 3/20 | 0.49 |
| ▸ | JAK3 | P52333 | 3/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 2/20 | 0.49 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23879073 | 0.90 | NTRK1 (0.50) | AURKAPAK4NTRK1TYK2JAK3 | |
| SCHEMBL23878992 | 0.90 | AURKA (0.59) | AURKANTRK1TYK2JAK3JAK2 | |
| SCHEMBL22054197 | 0.89 | GPR119 (0.52) | AURKAPAK4NTRK1NTRK3NTRK2 | |
| SCHEMBL22054006 | 0.89 | TYK2 (0.60) | AURKAPAK4NTRK1NTRK3NTRK2 | |
| SCHEMBL30147224 | 0.89 | GPR119 (0.52) | AURKAPAK4NTRK1NTRK3NTRK2 | |
| SCHEMBL23878805 | 0.88 | AURKA (0.53) | AURKAPAK4TYK2JAK3JAK2 | |
| SCHEMBL23878775 | 0.85 | AURKA (0.51) | AURKATYK2JAK3JAK2JAK1 | |
| SCHEMBL23878848 | 0.85 | AURKA (0.56) | AURKANTRK1TYK2JAK3JAK2 | |
| SCHEMBL23878737 | 0.84 | TYK2 (0.45) | AURKAPAK4TYK2JAK3JAK2 | |
| SCHEMBL23878966 | 0.84 | TYK2 (0.50) | AURKATYK2JAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| EP-3889152-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | AURKA 1417/4885PAK4 542/4885NTRK1 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.